Feature | Cardiovascular Business | Dave Fornell
After five years of almost constant lobbying efforts and numerous attempts by the U.S. House to push through a repeal of ...
February 10, 2016
News | Stents
CeloNova BioSciences Inc. announced this week that the first patient has been enrolled in its COBRA REDUCE trial. The COBRA REDUCE trial recently received conditional U.S. Food and Drug Administration (FDA) approval and will study the Cobra PzF nanocoated coronary stent (NCS) system in patients at high risk of bleeding.
February 10, 2016
News | Structural Heart
February 10, 2016 — HeartWare International Inc. and Valtech Cardio Ltd. announced the termination of HeartWare's ...
February 10, 2016Sponsored Content
Feature | Information Technology
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
March 21, 2024
News | Heart Failure
In a finding that could lead to new drugs to treat heart failure, researchers have uncovered the molecular mechanism that regulates how the heart pumps blood.
February 10, 2016News | Cardiovascular Business
February 9, 2016 — Cigna has entered into an outcomes-based contract with the pharmaceutical company Novartis for the ...
February 09, 2016
News | Heart Valve Technology
Valtech Cardio Ltd. announced that it has received German Neue Untersuchungs und Behandlungsmethoden (NUB) Status 1 approval for the Cardioband Mitral Reconstruction System, its flagship device for addressing mitral regurgitation in heart failure patients.
February 09, 2016Sponsored Content
Feature | Cardiac Imaging
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
March 05, 2024
News | Cardiac Diagnostics
Mount Sinai Heart is undertaking a three-year study to determine whether a workplace-based lifestyle intervention, accompanied by imaging data, will reduce the prevalence of cardiovascular (CV) disease risk factors related to lifestyle.
February 09, 2016
News | Stem Cell Therapies
Columbia Engineering researchers have shown, for the first time, that electrical stimulation of human heart muscle cells (cardiomyocytes) engineered from human stem cells aids their development and function.
February 09, 2016
News | ACC
The following are the late-breaking clinical trial presentations presented at the 2016 American College of Cardiology ...
February 09, 2016Sponsored Content
Blog
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
December 11, 2023
Technology | Left Atrial Appendage (LAA) Occluders
February 9, 2016 — Boston Scientific Corp. announced the Centers for Medicare and Medicaid Services (CMS) will cover ...
February 09, 2016
Feature | Heart Valve Technology | Dave Fornell
Off-label use of the St. Jude Amplatzer vascular plug devices offers a new solution for the minimally invasive repair of ...
February 08, 2016News | Cardiac Diagnostics
February 8, 2016 — A parent’s incarceration has immediate, devastating effects on a family. Now, Virginia Tech and ...
February 08, 2016Sponsored Content
Case Study | Hemodynamic Monitoring Systems
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
November 14, 2023
News | Patient Engagement
MedStar Heart & Vascular Institute at MedStar Washington Hospital Center is one of two hospitals in the nation selected to partner with the American College of Cardiology (ACC) on the Find Your Heart a Home pilot program.
February 08, 2016
Technology | Intravascular Imaging
St. Jude Medical Inc. announced the launch of the company’s Optis Mobile System in Japan and Europe. The diagnostic system is designed to couple state-of-the-art optical coherence tomography (OCT) and angiography co-registration with fractional flow reserve (FFR) technology into one portable system for hospitals with multiple catheterization labs.
February 08, 2016
News | Stents Peripheral
Stentys announced the first distribution agreements for its drug-eluting stent for treating below-the-knee (BTK) arteries in Germany and Belgium, making it the first self-expanding drug-eluting stent commercialized for this indication in Europe.
February 08, 2016© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now